- Custom Synthesis
- Catalog Products
- Melusine® Venom Libraries
- Clinalfa
- Clinalfa Basic
- Angiotensin II Acetate 50 µg/vial (Clinalfa basic)
- Angiotensin I/II (1-7) (human) Acetate 10 mg/vial (Clinalfa basic)
- (Pyr1)-Apelin-13 Acetate 1 mg/vial (Clinalfa basic)
- BQ-123 Sodium salt 5 mg/vial (Clinalfa basic)
- BQ-788 Sodium salt 1 mg/vial (Clinalfa basic)
- Bradykinin Acetate 50 µg/vial (Clinalfa basic)
- CCK-4 Acetate 50 µg/vial (Clinalfa basic)
- CRF (ovine) Acetate 100 µg/vial (Clinalfa basic)
- Exendin (9-39) Acetate 10 mg/vial (Clinalfa basic)
- Ghrelin (human) Acetate 100 µg/vial (Clinalfa basic) (formulated)
- GIP Acetate 500 µg/vial (Clinalfa basic)
- GLP-1 (7-36) amide Acetate 100 µg/vial (Clinalfa basic)
- Neuropeptide Y (human, rat) Acetate 200 µg/vial (Clinalfa basic)
- L-NMMA Acetate 250 mg/vial (Clinalfa basic)
- Pentagastrin 50 µg/vial (Clinalfa basic)
- Substance P Acetate 50 µg/vial (Clinalfa basic)
- Clinalfa Basic
- Contact
Pentagastrin 50 µg/vial (Clinalfa basic)
| Molecular Formula C37H49N7O9S |
| Relative Molecular Mass 767.90 g/mol |
| CAS-Number 5534-95-2 |
Contact Us
Pentagastrin 50 µg/vial (Clinalfa basic)
U-1100, 4056510
Sequence
Boc-β-Ala-Trp-Met-Asp-Phe-NH2
To be used in approved clinical trials only
Active Substance
Pentagastrin stimulates the secretion of gastric acid. It is a highly selective CCK-8 receptor agonist with panicogenic and anxiogenic properties. The peptide elicits symptoms and cardiovascular responses similar to those produced by CCK-4.
Literature References
A considerable number of publications on Clinalfa products used in clinical trials are available. The most important publications are listed here.
Note
This product is also available as cGMP API and in research grade quality (non GMP)
| Pentagastrin | |
| Pentagastrin (AY 6608, ICI 50123, NSC 367746, Boc-(β-Ala13)-Gastrin (13-17), Boc-β-Ala-CCK-4) |